Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of capecitabine, oxaliplatin and bevacizumab in advanced or metastatic colorectal cancer
jRCT2080220262Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and bevacizumab in metastatic colon cancer (mCRC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080220262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220262.